Key result
Pregnancy is well tolerated in patients with arrhythmogenic right ventricular cardiomyopathy despite the high risk of arrhythmias and heart failure.
Why the study?
Most pregnancy outcomes in arrhythmogenic right ventricular cardiomyopathy have only recently been reported, despite the condition posing risks of arrhythmias and heart failure under the physiological stress of pregnancy.
What is the evidence-based management of arrhythmogenic right ventricular cardiomyopathy (ARVC) during pregnancy?
What is the evidence-based management of arrhythmogenic right ventricular cardiomyopathy (ARVC) during pregnancy?
This review highlights that despite the high risk of arrhythmias and heart failure, pregnancy is generally well tolerated in patients with ARVC.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder resulting in fibrofatty replacement of the myocardium. Genetic mutations in genes encoding for desmosome proteins result in a ventricular myocardium prone to arrhythmias and heart failure. Although ARVC is known for a few decades, most of the outcomes in pregnancy are reported recently. Pregnancy leads to significant physiological changes with excess mechanical stress on the myocardium. All the retrospective studies suggest that pregnancy is well tolerated in these patients despite the high risk of arrhythmias and heart failure. Our review focuses on the most up-to-date evidence on the management of ARVC patients during the antepartum and postpartum period.
No takes yet. Share an insight, caveat, or question.
Khosla et al. (2020) conducted a review in Arrhythmogenic right ventricular cardiomyopathy (ARVC) in pregnancy. Pregnancy was evaluated. Pregnancy is well tolerated in patients with arrhythmogenic right ventricular cardiomyopathy despite the high risk of arrhythmias and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: